Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Neuropathy;Peripheral: early-phase trial registry

1 of 7 indexed Neuropathy;Peripheral trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Neuropathy;Peripheral: 7 US clinical trials tracked, 1 recruiting.

Neuropathy;Peripheral is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Bexion Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition neuropathyperipheral

OPEN 1 | RECR 14% | LATE 0 | EARLY 3 | RANK #2497 | SPON 1

Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%Neuropathy;Peripheral (this)14%
Open-enrollment share among volume-matched conditions near Neuropathy;Peripheral

Neuropathy;Peripheral lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neuropathy;Peripheral on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neuropathy;Peripheral is recruiting below its size-band peers.

    1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Neuropathy;Peripheral trials is spread across many organizations.

    Bexion Pharmaceuticals accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Neuropathy;Peripheral trials plan to enrol fewer than 100 people.

    Median target enrolment is 24 among the 7 trials that report a genuine target (sentinel values excluded). 7 of those (100%) plan for fewer than 100 participants.

  4. Neuropathy;Peripheral research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on Neuropathy;Peripheral records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

EXCAP Exercise Behavioral
1 trials
Abbott® DRG / Abbott®/Medtronic® SCS Device
1 trials
SensoniQ Treatment Station Device
1 trials
Diffusion Tensor Imaging Procedure
1 trials
BXQ-350 Drug
1 trials
Erchonia® EVRL™ Device
1 trials
Nutrition Education Behavioral
1 trials
Control Group Other
1 trials

US sites by state

Facility locations filed on Neuropathy;Peripheral trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
Ohio 1 trials
New York 1 trials
Maryland 1 trials
Massachusetts 1 trials
Georgia 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neuropathy;Peripheral page

7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuropathy;Peripheral condition card totals 7 registered trials; most-linked intervention EXCAP Exercise; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.